Press releases

20 May 2022

Disposal of own shares

18 May 2022

Transparency notification Wellington

13 May 2022

Disposal of own shares

13 May 2022

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

10 May 2022

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

2 May 2022

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

Press releases

Press releases

Search Press releases

Disposal of own shares

Transparency notification Wellington

Disposal of own shares

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Final analysis of open-label extension (OLE) study of Fintepla[®]▼ (fenfluramine) in Lennox-Gastaut...

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Disposal of own shares

Transparency notification Wellington

Disposal of own shares

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)

Choose a Country